Wealth Enhancement Advisory Services LLC Makes New Investment in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Wealth Enhancement Advisory Services LLC acquired a new stake in Organogenesis Holdings Inc. (NASDAQ:ORGO) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 33,608 shares of the company’s stock, valued at approximately $96,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Pallas Capital Advisors LLC acquired a new stake in shares of Organogenesis in the second quarter worth approximately $38,000. Delap Wealth Advisory LLC acquired a new stake in Organogenesis during the 2nd quarter worth $40,000. Allspring Global Investments Holdings LLC grew its holdings in shares of Organogenesis by 4,989.9% during the second quarter. Allspring Global Investments Holdings LLC now owns 15,677 shares of the company’s stock worth $44,000 after buying an additional 15,369 shares in the last quarter. Mackenzie Financial Corp raised its position in shares of Organogenesis by 46.1% in the second quarter. Mackenzie Financial Corp now owns 24,328 shares of the company’s stock valued at $68,000 after buying an additional 7,678 shares during the last quarter. Finally, CWM LLC lifted its stake in shares of Organogenesis by 301.8% in the second quarter. CWM LLC now owns 25,617 shares of the company’s stock worth $72,000 after buying an additional 19,242 shares in the last quarter. 49.57% of the stock is currently owned by hedge funds and other institutional investors.

Organogenesis Stock Performance

ORGO opened at $3.45 on Wednesday. The firm has a market capitalization of $457.37 million, a PE ratio of -26.92 and a beta of 1.60. The company has a current ratio of 2.73, a quick ratio of 2.42 and a debt-to-equity ratio of 0.22. Organogenesis Holdings Inc. has a twelve month low of $2.12 and a twelve month high of $4.70. The firm’s 50-day moving average price is $2.92 and its 200 day moving average price is $2.79.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.